Baczartan

Management of HTN.

HTN 50 mg once daily, increased to 100 mg daily as single dose or in 2 divided doses if necessary. Patient w/ intravascular fluid depletion Initially 25 mg once daily. Childn 20-50 kg 25 mg once daily. Childn ≥6 yr May be given an initial dose of 700 mcg/kg once daily w/ max 50 mg adjusted according to response. Diabetic nephropathy Initially 50 mg daily, increased to 100 mg once daily depending on BP.

May be taken with or without food.

Hypersensitivity.

Hypersensitivity. Not recommended in patients w/ primary aldosteronism. Dual blockade of RAAS through combined use of ACE inhibitors or aliskiren is not recommended. Not to be used concomitantly w/ ACE inhibitors in patients w/ diabetic nephropathy. Excessive BP decrease in patients w/ ischaemic CV & cerebrovascular disease could result in MI or stroke. Patients w/ bilateral renal artery stenosis of the artery to a solitary kidney; recent kidney transplantation; heart failure & concomitant severe renal impairment, w/ severe heart failure (NYHA class IV) as well as w/ heart failure & symptomatic life-threatening cardiac arrhythmias; suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Black patients. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Closely monitor patients w/ history of angioedema (swelling of the face, lips, throat, &/or tongue); plasma conc of K & CrCl especially in patients w/ heart failure & CrCl 30-50 mL/min. Correct vol- &/or Na-depletion prior to administration. Regularly monitor renal function during treatment. Not recommended in concomitant use w/ K-sparing diuretics, K supplements, K-containing salt substitutes, or other drugs that may increase serum K eg, trimethoprim-containing products; ACE inhibitors. Combination w/ β-blocker. Not recommended during 1st trimester & contraindicated during 2nd & 3rd trimester of pregnancy. Not recommended during lactation. Not recommended in childn w/ hepatic impairment; GFR <30 mL/min/1.73 m².

Dizziness & dose-related orthostatic hypotension; impaired renal function & rarely rash, angioedema & raised ALT; hyperkalemia, myalgia & arthralgia. Resp tract disorders, back pain, GI disturbances, fatigue, neutropenia, & rhabdomyolysis.

Antihypertensive effects may be potentiated w/ drugs or other agents that lower BP. Risk of renal impairment may be increased & hypotensive effect may be attenuated w/ NSAIDs. Drugs metabolized by cytochrome P450 isoenzyme.

Angiotensin II Antagonists

C09CA01 - losartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx